FINWIRES · TerminalLIVE
FINWIRES

Evolution Mining Seeks to Establish Independent Mill Feed Ore Source to Extend Queensland Operations; Shares Down 4%

By

Evolution Mining (ASX:EVN) seeks to establish the Bert orebody as an independent mill feed ore source at the Ernest Henry operations in Queensland, according to a Tuesday Australian bourse filing.

Bert is projected to add around 6,000 tonnes per year of copper and around 12,000 ounces per year of gold to mill capacity at the operations. First ore is expected from the Bert project in fiscal 2029.

It is studying near-term options to unlock value while maintaining optionality on the way to creating a tier one operation at the Cowal mine in New South Wales.

An integrated open pit and cave production strategy at the Northparkes copper project, also in New South Wales, de-risks delivery while maximizing asset value.

An expansion study at the copper project includes pre-feasibility studies on the MJH block cave as well as E44, Major Tom, and E51 open pits. It also includes concept studies on three block caves, E48L2, E26L3,and GRP. The studies are due for completion in fiscal 2027.

The company's shares fell almost 4% in recent Tuesday trade.

What else is happening in Asia?

Asia

Orora Chief Safety, Sustainability, Governance Officer to Step Down at End of Year

Orora (ASX:ORA) said Ann Stubbings plans to step down as chief safety, sustainability, and governance officer, effective Dec. 31, after more than 13 years with the packaging products firm, according to a Monday filing with the Australian bourse.In addition, Susannah Jobling Hodgens will be appointed as chief legal officer, the company said. Hodgens has worked with Orora for 13 years in senior legal and governance roles, most recently as general counsel and alternate company secretary.Orora shares gained nearly 1% in recent Monday trade.

ASX:ORA
Asia

Biokin Pharma Enrolls First Patient in Phase Three Trial for Breast Cancer Drug; Shares Up 4%

Sichuan Biokin Pharmaceutical (SHA:688506) enrolled the first subject for the third-phase clinical trial of biologic drug T-Bren for injection, according to a weekend filing with the Shanghai bourse.The trial evaluates T-Bren combined with pertuzumab versus standard chemotherapy in neoadjuvant treatment of HER2-positive breast cancer, according to a weekend filing with the Shanghai bourse.Shares of the pharmaceutical company rose 4% in recent trade.

SHA:688506
Asia

Market Chatter: Korea Exchange to Extend Trading Hours till 8PM

South Korea's main stock market, the Korea Exchange, will enable trading till 8 pm following the regular close at 3:30 pm from Monday, in its move toward 24-hour trading, Bloomberg News reported Sunday.This decision opens 2,400 Korea Composite Stock Price Index, or Kospi, and Kosdaq stocks for evening trades, which include short-selling. The move excludes exchange-traded funds, the report said.The Korea Exchange plans to introduce pre-market trading by the end of next year, it said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

^KOSDAQKOSPI